UC-514321 - ≥98% , CAS No.299420-83-0
In stock
SKU
U647255
UC-514321, a structural analog of NSC370284 with higher activity, directly targets STAT3/5 and represses TET1 expression, but not TET2 or TET3. UC-514321 has the potential to treat acute myeloid leukemia (AML) both in vitro and in vivo, with low toxicity
In Vitro
UC-514321 increases apoptosis in AML cells not in normal HSPCs. UC-514321 (0-500 nM, 48 h) inhibits AML cells viability TET1-signaling dependently. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: MONOMAC-6, THP-1, KOCL-48, KASUMI-1, ML-2, and NB4 cells. Concentration: 0-500 nM. Incubation Time: 48 hours. Result: Most significantly repressed MONOMAC-6 cell viability. Showed no inhibitory effect on the viability of TET1-low AML. RT-PCRCell Line: MONOMAC-6 cells. Concentration: 0-500 nM. Incubation Time: 48 hours. Result: Functioned as TET1-transcription inhibitors in TET1-high AMLs and their anti-leukemic effects are TET1-dependent.
In Vivo
UC-514321 (2.5 mg/kg, ip, once per day, for 10 days) exhibits more potent anti-tumor activity than NSC370284 in AML mice models . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: MLL-AF9-AML mice and AE9a-AML model . Dosage: 2.5 mg/kg. Administration: IP., once per day, for 10 days. Result: Showed an improved therapeutic effect in AML mouse models in vivo. Prolonged the median survival over three fold.
Form:Solid
IC50& Target:STAT3 STAT5 TET1
More Information
| CAS | 299420-83-0 |
|---|---|
| Specifications & Purity | ≥98% |
| Storage | Store at -20°C |
| Shipped In | Ice chest + Ice pads |
| Product Description | UC-514321, a structural analog of NSC370284 with higher activity, directly targets STAT3/5 and represses TET1 expression, but not TET2 or TET3. UC-514321 has the potential to treat acute myeloid leukemia (AML) both in vitro and in vivo, with low toxicity In Vitro UC-514321 increases apoptosis in AML cells not in normal HSPCs. UC-514321 (0-500 nM, 48 h) inhibits AML cells viability TET1-signaling dependently. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: MONOMAC-6, THP-1, KOCL-48, KASUMI-1, ML-2, and NB4 cells. Concentration: 0-500 nM. Incubation Time: 48 hours. Result: Most significantly repressed MONOMAC-6 cell viability. Showed no inhibitory effect on the viability of TET1-low AML. RT-PCRCell Line: MONOMAC-6 cells. Concentration: 0-500 nM. Incubation Time: 48 hours. Result: Functioned as TET1-transcription inhibitors in TET1-high AMLs and their anti-leukemic effects are TET1-dependent. In Vivo UC-514321 (2.5 mg/kg, ip, once per day, for 10 days) exhibits more potent anti-tumor activity than NSC370284 in AML mice models . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: MLL-AF9-AML mice and AE9a-AML model . Dosage: 2.5 mg/kg. Administration: IP., once per day, for 10 days. Result: Showed an improved therapeutic effect in AML mouse models in vivo. Prolonged the median survival over three fold. Form:Solid IC50& Target:STAT3 STAT5 TET1 |
| Solubility | Ethanol : 50 mg/mL (113.23 mM; Need ultrasonic) DMSO : 25 mg/mL (56.62 mM; Need ultrasonic) |
| PubChem CID | 339892 |
Reviews
Customer Reviews
Remind me later